TIVOZANIB for Renal cell carcinoma: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 1,258 adverse event reports in the FDA FAERS database where TIVOZANIB was used for Renal cell carcinoma.
Most Reported Side Effects for TIVOZANIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Fatigue | 291 | 20.9% | 9 | 36 |
| Diarrhoea | 177 | 12.7% | 7 | 28 |
| Blood pressure increased | 144 | 10.3% | 6 | 21 |
| Nausea | 132 | 9.5% | 8 | 24 |
| Decreased appetite | 127 | 9.1% | 7 | 32 |
| Disease progression | 121 | 8.7% | 12 | 17 |
| Dysphonia | 109 | 7.8% | 3 | 13 |
| Death | 89 | 6.4% | 89 | 15 |
| Asthenia | 80 | 5.7% | 5 | 17 |
| Off label use | 73 | 5.2% | 3 | 8 |
| Pain | 68 | 4.9% | 5 | 16 |
| Hypertension | 66 | 4.7% | 5 | 12 |
| Vomiting | 63 | 4.5% | 3 | 20 |
| Dyspnoea | 52 | 3.7% | 4 | 22 |
| Constipation | 51 | 3.7% | 2 | 14 |
Other Indications for TIVOZANIB
Metastatic renal cell carcinoma (49)
Renal cancer (34)
Product used for unknown indication (18)
Clear cell renal cell carcinoma (7)
Neoplasm (6)
Other Drugs Used for Renal cell carcinoma
CABOZANTINIB S-MALATE (9,156)
NIVOLUMAB (6,514)
LENVATINIB (3,849)
PEMBROLIZUMAB (3,027)
SUNITINIB MALATE (2,926)
PAZOPANIB (2,799)
IPILIMUMAB (2,585)
AXITINIB (2,447)
EVEROLIMUS (1,573)
CABOZANTINIB (1,241)